Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Renal Cell Carcinoma-Pipeline Review, H1 2015

Metastatic Renal Cell Carcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Renal Cell Carcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Renal Cell Carcinoma-Pipeline Review, H1 2015', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Metastatic Renal Cell Carcinoma Overview 8

Therapeutics Development 9

Pipeline Products for Metastatic Renal Cell Carcinoma-Overview 9

Pipeline Products for Metastatic Renal Cell Carcinoma-Comparative Analysis 10

Metastatic Renal Cell Carcinoma-Therapeutics under Development by Companies 11

Metastatic Renal Cell Carcinoma-Therapeutics under Investigation by Universities/Institutes 15

Metastatic Renal Cell Carcinoma-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Metastatic Renal Cell Carcinoma-Products under Development by Companies 20

Metastatic Renal Cell Carcinoma-Products under Investigation by Universities/Institutes 23

Metastatic Renal Cell Carcinoma-Companies Involved in Therapeutics Development 24

Acceleron Pharma, Inc. 24

Activartis Biotech GmbH 25

AlphaMab Co., Ltd 26

Amgen Inc. 27

Angiogene Pharmaceuticals Ltd. 28

Argos Therapeutics, Inc. 29

Astellas Pharma Inc. 30

Beta Pharma, Inc. 31

Bionomics Limited 32

Cerulean Pharma, Inc. 33

Conkwest, Inc. 34

Debiopharm International S.A. 35

Eisai Co., Ltd. 36

Eli Lilly and Company 37

Epirus Biopharmaceuticals, Inc. 38

Exelixis, Inc. 39

Genor BioPharma Co., Ltd. 40

Hospira, Inc. 41

immatics biotechnologies GmbH 42

Immune Design Corp. 43

Immunicum AB 44

Inbiopro Solutions Pvt. Ltd. 45

Jiangsu Hengrui Medicine Co., Ltd. 46

Mabion SA 47

NewLink Genetics Corporation 48

Novartis AG 49

Ono Pharmaceutical Co., Ltd. 50

Panacea Biotec Limited 51

Peloton Therapeutics, Inc. 52

Prima BioMed Ltd. 53

Rexahn Pharmaceuticals, Inc. 54

Seattle Genetics, Inc. 55

Syndax Pharmaceuticals, Inc. 56

TVAX Biomedical, Inc. 57

Metastatic Renal Cell Carcinoma-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Target 59

Assessment by Mechanism of Action 62

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

AGS-003-Drug Profile 69

AGS-16C3F-Drug Profile 72

AGS-16M8F-Drug Profile 73

aldesleukin-Drug Profile 74

AV0-113-Drug Profile 75

bevacizumab biosimilar-Drug Profile 76

bevacizumab biosimilar-Drug Profile 77

bevacizumab biosimilar-Drug Profile 78

bevacizumab biosimilar-Drug Profile 79

bevacizumab biosimilar-Drug Profile 80

bevacizumab biosimilar-Drug Profile 81

bevacizumab biosimilar-Drug Profile 82

bevacizumab biosimilar-Drug Profile 83

BNC-105-Drug Profile 84

BNC-105P-Drug Profile 85

BPI-3119-Drug Profile 87

cabozantinib s-malate-Drug Profile 88

CRLX-101-Drug Profile 91

CST-101-Drug Profile 93

dalantercept-Drug Profile 95

Debio-0932-Drug Profile 97

Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma-Drug Profile 99

entinostat-Drug Profile 100

everolimus-Drug Profile 104

G-305-Drug Profile 109

Hyperacute For Renal Cancer-Drug Profile 110

IBPM-002BZ-Drug Profile 111

IMA-901-Drug Profile 112

IMP-321-Drug Profile 114

Intuvax-Drug Profile 116

lenvatinib-Drug Profile 117

LY-2510924-Drug Profile 121

Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma-Drug Profile 122

nivolumab (recombinant)-Drug Profile 123

Orellanine-Drug Profile 128

panobinostat-Drug Profile 129

PT-2385-Drug Profile 135

Recombinant Protein for Oncology-Drug Profile 136

rilotumumab-Drug Profile 137

RX-0201-Drug Profile 139

SGN-CD70A-Drug Profile 141

SHR-1020-Drug Profile 142

trebananib-Drug Profile 144

TVI-Kidney-1-Drug Profile 147

ZD-6126-Drug Profile 148

Metastatic Renal Cell Carcinoma-Recent Pipeline Updates 149

Metastatic Renal Cell Carcinoma-Dormant Projects 195

Metastatic Renal Cell Carcinoma-Discontinued Products 199

Metastatic Renal Cell Carcinoma-Product Development Milestones 200

Featured News & Press Releases 200

Appendix 209

Methodology 209

Coverage 209

Secondary Research 209

Primary Research 209

Expert Panel Validation 209

Contact Us 210

Disclaimer 210

List of Tables

Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12

Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Metastatic Renal Cell Carcinoma-Pipeline by Acceleron Pharma, Inc., H1 2015 27

Metastatic Renal Cell Carcinoma-Pipeline by Activartis Biotech GmbH, H1 2015 28

Metastatic Renal Cell Carcinoma-Pipeline by AlphaMab Co., Ltd, H1 2015 29

Metastatic Renal Cell Carcinoma-Pipeline by Amgen Inc., H1 2015 30

Metastatic Renal Cell Carcinoma-Pipeline by Angiogene Pharmaceuticals Ltd., H1 2015 31

Metastatic Renal Cell Carcinoma-Pipeline by Argos Therapeutics, Inc., H1 2015 32

Metastatic Renal Cell Carcinoma-Pipeline by Astellas Pharma Inc., H1 2015 33

Metastatic Renal Cell Carcinoma-Pipeline by Beta Pharma, Inc., H1 2015 34

Metastatic Renal Cell Carcinoma-Pipeline by Bionomics Limited, H1 2015 35

Metastatic Renal Cell Carcinoma-Pipeline by Cerulean Pharma, Inc., H1 2015 36

Metastatic Renal Cell Carcinoma-Pipeline by Conkwest, Inc., H1 2015 37

Metastatic Renal Cell Carcinoma-Pipeline by Debiopharm International S.A., H1 2015 38

Metastatic Renal Cell Carcinoma-Pipeline by Eisai Co., Ltd., H1 2015 39

Metastatic Renal Cell Carcinoma-Pipeline by Eli Lilly and Company, H1 2015 40

Metastatic Renal Cell Carcinoma-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41

Metastatic Renal Cell Carcinoma-Pipeline by Exelixis, Inc., H1 2015 42

Metastatic Renal Cell Carcinoma-Pipeline by Genor BioPharma Co., Ltd., H1 2015 43

Metastatic Renal Cell Carcinoma-Pipeline by Hospira, Inc., H1 2015 44

Metastatic Renal Cell Carcinoma-Pipeline by immatics biotechnologies GmbH, H1 2015 45

Metastatic Renal Cell Carcinoma-Pipeline by Immune Design Corp., H1 2015 46

Metastatic Renal Cell Carcinoma-Pipeline by Immunicum AB, H1 2015 47

Metastatic Renal Cell Carcinoma-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 48

Metastatic Renal Cell Carcinoma-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 49

Metastatic Renal Cell Carcinoma-Pipeline by Mabion SA, H1 2015 50

Metastatic Renal Cell Carcinoma-Pipeline by NewLink Genetics Corporation, H1 2015 51

Metastatic Renal Cell Carcinoma-Pipeline by Novartis AG, H1 2015 52

Metastatic Renal Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 53

Metastatic Renal Cell Carcinoma-Pipeline by Panacea Biotec Limited, H1 2015 54

Metastatic Renal Cell Carcinoma-Pipeline by Peloton Therapeutics, Inc., H1 2015 55

Metastatic Renal Cell Carcinoma-Pipeline by Prima BioMed Ltd., H1 2015 56

Metastatic Renal Cell Carcinoma-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 57

Metastatic Renal Cell Carcinoma-Pipeline by Seattle Genetics, Inc., H1 2015 58

Metastatic Renal Cell Carcinoma-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 59

Metastatic Renal Cell Carcinoma-Pipeline by TVAX Biomedical, Inc., H1 2015 60

Assessment by Monotherapy Products, H1 2015 61

Number of Products by Stage and Target, H1 2015 63

Number of Products by Stage and Mechanism of Action, H1 2015 66

Number of Products by Stage and Route of Administration, H1 2015 69

Number of Products by Stage and Molecule Type, H1 2015 71

Metastatic Renal Cell Carcinoma Therapeutics-Recent Pipeline Updates, H1 2015 152

Metastatic Renal Cell Carcinoma-Dormant Projects, H1 2015 198

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..1), H1 2015 199

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..2), H1 2015 200

Metastatic Renal Cell Carcinoma-Dormant Projects (Contd..3), H1 2015 201

Metastatic Renal Cell Carcinoma-Discontinued Products, H1 2015 202

List of Figures

Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12

Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 61

Number of Products by Top 10 Targets, H1 2015 62

Number of Products by Stage and Top 10 Targets, H1 2015 62

Number of Products by Top 10 Mechanism of Actions, H1 2015 65

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 65

Number of Products by Top 10 Routes of Administration, H1 2015 68

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 68

Number of Products by Top 10 Molecule Types, H1 2015 70

Number of Products by Stage and Top 10 Molecule Types, H1 2015 71

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Activartis Biotech GmbH

AlphaMab Co., Ltd

Amgen Inc.

Angiogene Pharmaceuticals Ltd.

Argos Therapeutics, Inc.

Astellas Pharma Inc.

Beta Pharma, Inc.

Bionomics Limited

Cerulean Pharma, Inc.

Conkwest, Inc.

Debiopharm International S.A.

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Exelixis, Inc.

Genor BioPharma Co., Ltd.

Hospira, Inc.

immatics biotechnologies GmbH

Immune Design Corp.

Immunicum AB

Inbiopro Solutions Pvt. Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Mabion SA

NewLink Genetics Corporation

Novartis AG

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

Peloton Therapeutics, Inc.

Prima BioMed Ltd.

Rexahn Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Syndax Pharmaceuticals, Inc.

TVAX Biomedical, Inc.

Metastatic Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Metastatic Renal Cell Carcinoma Therapeutics, Metastatic Renal Cell Carcinoma Pipeline Overview, Metastatic Renal Cell Carcinoma Pipeline, Metastatic Renal Cell Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com